MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 855 - 855

Published: April 2, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic influenced by genetic, lifestyle, and environmental factors. While MASLD more prevalent in men, women are at increased risk after menopause, highlighting critical pathogenetic role of sex hormones. The complex interplay between estrogen deficiency, visceral fat accumulation, metabolic syndrome (MetS), inflammation accelerates progression, increases cardiovascular (CV) risk, triggers a cycle worsening adiposity, dysfunction, psychological problems, including eating disorders. Weight loss postmenopausal can significantly improve both outcomes, helping to prevent related conditions. This review examines prevalence MASLD, its comorbidities (type 2 diabetes T2D, CV, mental disorders), mechanisms, pharmacological treatment with GLP-1 receptor agonists (GLP1-RAs), focus on women. Given use GLP1-RAs obesity T2D patients, increase MetS this analyzes potential stable GLP-1–estrogen conjugate as therapeutic approach subgroup. By combining synergistic effects hormones, dual agonist has been shown food intake reward suppression, resulting greater weight improved insulin sensitivity, glucose, lipid metabolism. Therefore, we hypothesize that pharmacotherapy may provide targeted benefits than either hormone alone protecting liver, β-cells, overall health. As these only supported preclinical data, highlights need for future research evaluate confirm mechanisms efficacy clinical settings, particularly

Language: Английский

Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)

International Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 4(4), P. 782 - 809

Published: Dec. 9, 2024

Sex differences are a complex and crucial variable in developing progressing metabolic cardiovascular disease pathophysiology clinical outcomes. The female sex, compared to the male is protected from disturbances their resulting events. However, peculiar life phases associated with females, such as puberty, pregnancy, premenopausal menopausal stages, all different risks for development of (CVD). Metabolic dysfunction-associated steatotic liver (MASLD), condition hepatic steatosis, at least one feature syndrome an increased risk MASLD its progression CVD differs between men women. Differences several factors, including formyl peptide receptor (FPR) 2, adipose tissue distribution, pyruvate kinase (LPK), ketone body production, may underlie sex MASLD-induced CVD. Understanding specific factors involved sexes crucial. This knowledge will provide important insights into mechanisms responsible complications can potentially lead therapeutics targeted explicitly each offering new hope fight against

Language: Английский